Free Trial Information
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
Read More
BioCentury | Jul 14, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-196b (miR-196b)

...culture and mouse studies suggest miR-196b could help treat lung cancer. Levels of inactive, methylated miR-196b...
...patients than in samples from healthy volunteers. In a human lung cancer cell line, a miR-196b...
...identifying and testing promoters of miR-196b expression in animal models of lung cancer. TARGET/MARKER/PATHWAY: MicroRNA-196b (miR-196b...
Read More
BioCentury | Aug 20, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-196a (miR-196a); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc); homeobox B7 (HOXB7)

Cancer INDICATION: Breast cancer Studies in patient samples, cell culture and mice suggest miR-196a or inhibition of MYC could help treat tamoxifen-resistant breast cancer. In tumors from estrogen receptor-positive breast cancer patients previously treated with...
Read More
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Cancer

...myelogenous leukemia (AML) MicroRNA-196b (miR-196b); miR-21 Patient sample, mouse and in vitro studies suggest inhibiting miR-196b...
...to the promoter of miR-196 and miR-21. In bone marrow cells from Hoxa9 knockout mice, miR-196b...
...cells from wild-type mice. In a mouse model of Hoxa9-dependent AML, injection of antagomirs targeting miR-196b...
Read More
BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Huntingtin (HTT); microRNA-196a (miR-196a) Mouse and cell culture studies suggest miR-196a could help treat HD. In a mouse model for HD, miR-196a...
Read More
BioCentury | Jun 28, 2012
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal and bulbar muscular atrophy (SBMA) MicroRNA-196a (miR-196a) Studies in cell culture and in mice suggest viral delivery of miR-196a could...
Read More
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Gastrointestinal cancer MicroRNA-196a (miR-196a); HOX transcript antisense RNA (HOTAIR) Patient sample and cell culture studies suggest miR-196a or HOTAIR could be...
Read More
BioCentury | Jun 1, 2009
Emerging Company Profile

Asuragen: Cutting pancreatic surgeries

Patients with pancreatic cancer and pancreatitis present with similar symptoms, and are often given ultrasound tests to confirm the presence or absence of lesions. About 15% of these tests are inconclusive, and as a result...
Read More
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Hematology

...Licensing status Publication and contact information Hematology Neutropenia Growth factor independent 1 transcription repressor (GFI1); microRNA-196b...
Read More
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Cancer

...Target/ marker/ pathway Summary Licensing status Publication and contact information Cancer Leukemia; mixed-lineage leukemia (MLL) MicroRNA-196b...
Read More
Items per page:
1 - 10 of 10